Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.

× No keyword cloud information.

27 in total

1. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.

Authors: Inkeun Park; Hyo Jin Lee; Woo Kyoon Bae; Shinkyo Yoon; Jae Lyun Lee
Journal: Invest New Drugs Date: 2019-06-24 Impact factor: 3.850

Review 2. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226

3. Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava.

Authors: Tomochika Shinagawa; Hideaki Ito; Yasuhiro Sakai; Shuji Mikami; Hideki Oe; Minekatsu Taga; Osamu Yokoyama
Journal: Int Cancer Conf J Date: 2019-06-18

4. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.

Authors: Yasuhiro Iribe; Mitsuko Furuya; Yousuke Shibata; Masato Yasui; Makoto Funahashi; Junichi Ota; Hiromichi Iwashita; Yoji Nagashima; Hisashi Hasumi; Narihiko Hayashi; Kazuhide Makiyama; Keiichi Kondo; Reiko Tanaka; Masahiro Yao; Noboru Nakaigawa
Journal: Fam Cancer Date: 2020-07-15 Impact factor: 2.375

Review 5. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.

Authors: Maria I Carlo; Martin H Voss; Robert J Motzer
Journal: Nat Rev Urol Date: 2016-06-21 Impact factor: 14.432

Review 6. Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors: Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal: Oncoimmunology Date: 2016-02-18 Impact factor: 8.110

7. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components.

Authors: Brandon J Manley; James J Hsieh
Journal: Transl Cancer Res Date: 2016-08 Impact factor: 1.241

Review 8. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.

Authors: Matthew Zibelman; Elizabeth R Plimack
Journal: J Natl Compr Canc Netw Date: 2017-06 Impact factor: 11.908

9. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.

Authors: Diego A Adrianzen Herrera; Sarah B Fleisig; Benjamin A Gartrell
Journal: Invest New Drugs Date: 2017-05-02 Impact factor: 3.850

10. Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.

Authors: Tim N Beck; Erica A Golemis; Daniel M Geynisman
Journal: Eur Urol Date: 2016-03-03 Impact factor: 20.096